Alkermes plc $ALKS Shares Bought by Maryland State Retirement & Pension System

Maryland State Retirement & Pension System grew its position in Alkermes plc (NASDAQ:ALKS – Free Report) by 54.1% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 37,347 shares of the company’s stock after purchasing an additional 13,105 shares during the period. Maryland State Retirement & Pension System’s holdings in Alkermes were worth $1,513,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Illinois Municipal Retirement Fund raised its holdings in shares of Alkermes by 36.2% during the third quarter. Illinois Municipal Retirement Fund now owns 114,142 shares of the company’s stock valued at $4,625,000 after acquiring an additional 30,368 shares during the period. M&G PLC purchased a new stake in shares of Alkermes in the 3rd quarter valued at approximately $14,368,000. Allspring Global Investments Holdings LLC lifted its position in shares of Alkermes by 236.1% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 85,682 shares of the company’s stock valued at $3,474,000 after acquiring an additional 60,188 shares in the last quarter. Pictet Asset Management Holding SA boosted its stake in Alkermes by 20.4% in the 3rd quarter. Pictet Asset Management Holding SA now owns 1,009,318 shares of the company’s stock worth $41,012,000 after purchasing an additional 171,292 shares during the period. Finally, CenterBook Partners LP boosted its stake in Alkermes by 88.3% in the 3rd quarter. CenterBook Partners LP now owns 13,938 shares of the company’s stock worth $565,000 after purchasing an additional 6,535 shares during the period. 95.21% of the stock is currently owned by institutional investors and hedge funds.

Alkermes Price Performance

Shares of Alkermes stock opened at $47.03 on Monday. The firm has a market cap of $7.90 billion, a price-to-earnings ratio of -2,350.32 and a beta of 0.32. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.42 and a quick ratio of 2.02. Alkermes plc has a 52-week low of $27.00 and a 52-week high of $55.67. The stock has a 50-day simple moving average of $43.67 and a 200-day simple moving average of $41.13.

Alkermes (NASDAQ:ALKS – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.17. Alkermes had a positive return on equity of 0.40% and a negative net margin of 0.02%. The firm had revenue of $480.13 million for the quarter, compared to the consensus estimate of $463.48 million. During the same quarter in the prior year, the company posted $0.49 earnings per share. The firm’s revenue was up 21.8% on a year-over-year basis. On average, equities research analysts expect that Alkermes plc will post -0.52 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Alkermes news, EVP David Gaffin sold 2,035 shares of the business’s stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $46.17, for a total value of $93,955.95. Following the completion of the sale, the executive vice president directly owned 219,353 shares of the company’s stock, valued at $10,127,528.01. The trade was a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Craig Hopkinson sold 9,000 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $46.99, for a total transaction of $422,910.00. Following the transaction, the executive vice president owned 65,389 shares in the company, valued at approximately $3,072,629.11. This trade represents a 12.10% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 15,103 shares of company stock valued at $697,973 over the last quarter. Corporate insiders own 4.59% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and set a $62.00 price objective on shares of Alkermes in a research report on Monday, September 21st. Stifel Nicolaus restated a “buy” rating and issued a $63.00 target price (up from $45.00) on shares of Alkermes in a report on Monday, July 20th. HC Wainwright increased their target price on Alkermes from $43.00 to $50.00 and gave the company a “neutral” rating in a report on Wednesday, November 4th. Wells Fargo & Company raised their target price on Alkermes from $65.00 to $68.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 4th. Finally, Piper Sandler reiterated an “overweight” rating and set a $65.00 price target (up from $43.00) on shares of Alkermes in a report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $55.73.

View Our Latest Stock Report on ALKS

Alkermes Company Profile

(Free Report)

Alkermes plc is a biopharmaceutical company focused on developing and commercializing medicines for neuroscience-related conditions, including serious mental illness and addiction. Founded in 1987, the company has operations in the United States and Ireland, with its corporate headquarters in Dublin and major U.S. operations in Massachusetts. Its marketed medicines include Vivitrol, an extended-release injectable formulation of naltrexone used to treat alcohol dependence and to prevent relapse to opioid dependence after detoxification; Aristada, an injectable treatment for schizophrenia in adults; and Lybalvi, a medicine for schizophrenia and bipolar I disorder in adults.

See Also

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes plc (NASDAQ:ALKS – Free Report).

Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.